## Abstract Vaccines based on human papillomavirus (HPV) 16 and 18 virus‐like particles have the potential to prevent ∼70% of cervical cancers. In Australia, public vaccination against HPV commenced in April 2007, and includes routine vaccination of females aged 12–13 years, and a 2‐year school and
Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates
✍ Scribed by André Berchtold; Pierre-André Michaud; Denise Nardelli-Haefliger; Joan-Carles Surís
- Publisher
- SP Birkhäuser Verlag Basel
- Year
- 2009
- Tongue
- English
- Weight
- 355 KB
- Volume
- 55
- Category
- Article
- ISSN
- 1661-8556
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract High‐risk human papillomaviruses (HR‐HPVs) are the causative agents of cervical cancer and prophylactic HPV vaccination has been recommended for adolescents but no data are available on the prevalence of HPV infection among adolescents in India. Self‐collected midstream urine samples fr
## Abstract Cervical cancer is a leading cause of cancer‐related deaths in developing countries, and the human papillomavirus (HPV) is linked etiologically to cervical cancer. Hence, a vaccine which prevents HPV‐associated cervical cancer would have the most impact in developing countries, includin
## Abstract A large proportion of human papillomavirus (HPV) infections is sustained by multiple genotypes. The effect of multiple infections on the risk of cervical intraepithelial neoplasia (CIN) and the potential efficacy of vaccine on these infections are controversial. We performed viral typin